Hualan Vac(SZ:301207) Xiangcai Securities·2025-08-17 13:31Investment Rating - The industry investment rating is maintained at "Overweight" [1] Core Views - The first vaccine product has passed the commercial insurance innovative drug directory review, potentially opening new payment channels for innovative vaccines [3] - The vaccine industry is currently facing performance pressure due to supply-demand imbalances, but long-term prospects remain positive driven by innovation and international expansion [7][29] Summary by Sections Domestic and International Vaccine Dynamics - Hualan Vaccine has received approval for clinical trials of a freeze-dried type B Haemophilus influenzae conjugate vaccine, which is expected to provide protection against infections caused by this pathogen [3] - The "Quadrivalent Influenza Virus Subunit Vaccine" has become the only vaccine to pass the preliminary review for the commercial insurance innovative drug directory, marking a significant step in integrating vaccines into the insurance payment system [3] Market Review - The vaccine sector saw a 1.3% increase last week, with a cumulative increase of 2.28% in 2025 [4][5] - The overall pharmaceutical sector reported a 3.08% increase, with various sub-sectors showing mixed performance [4][10] Valuation - The vaccine sector's PE (ttm) is 81.82X, with a PB (lf) of 1.99X, indicating a slight increase from the previous week [6] Investment Recommendations - The vaccine industry is experiencing performance pressure in 2024 and Q1 2025, but companies are focusing on pipeline adjustments and innovation to improve competitiveness [7][26] - Long-term investment focus should be on companies with strong R&D capabilities and differentiated products, with recommendations for Kangxino and Kanghua Biotech [29]